The burden of HIV-associated cryptococcal disease

AIDS

Volumn 23, Issue 4, 2009, Pages 531-532

  Harrison, Thomas S ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; FLUCONAZOLE;

ANTIBIOTIC PROPHYLAXIS; CD4 LYMPHOCYTE COUNT; CRYPTOCOCCAL MENINGITIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MEGADOSE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MORBIDITY; MORTALITY; NOTE; PRIORITY JOURNAL;

AFRICA SOUTH OF THE SAHARA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; HUMANS; INCIDENCE; MENINGITIS, CRYPTOCOCCAL; WORLD HEALTH;

EID: 62349102448     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328322ffc3     Document Type: Note

References (11)

1. Park B, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller T. Estimation of the global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS (in press).
2. McCarthy KM, Morgan J, Wannemuehler KA, Mirza SA, Gould SM, Mhlongo M, et al. Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS 2006; 20:2199-2206.
3. Kambugu AD, Meya DB, Rhein J, O'Brien M, Janoff EN, Ronald AR, et al. Outcomes of cryptocccal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008; 46:1694-1701.
4. Longley N, Muzoora C, Taseera K, Mwesigye J, Rwebembera J, Chakera A, et al. Dose-response effect of high dose fluconazole for HIV-associated cryptococcal meningitis in Southwest Uganda. Clin Infect Dis 2008; 47:1556-1561.
5. Schaars CF, Meintjes GA, Morroni C, Post FA, Maartens G. Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. BMC Infect Dis 2006; 6:118.
6. Okongo M, Morgan D, Mayanja B, Ross A, Whitworth J. Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. Int J Epidemiol 1998; 27:698-702.
7. French N, Gray K, Watera C, Nakiyingi J, Lugada E, Moore M, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002; 16:1031-1038.
8. Corbett EL, Churchyard GJ, Charalambos S, Samb B, Moloi V, Clayton TC, et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002; 34:1251-1258.
9. Cloete K, Boulle A, Osler M. Antiretroviral programme outcomes at 4 years in the Western Cape Province [abstract #474]. 3rd South African AIDS Conference, 2007; Durban, South Africa, http:// www.sa-aidsconference. com/Presentations/Cloete.Keith.pdf.
10. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenaemia in patients accessing an antiretroviral treatment program in South Africa [abstract #P-C-24]. In: Program and Abstracts, 7th International Conference on Cryptococcus and Cryptococcosis; September 2008; Nagasaki, Japan.
11. Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, Bekker L-G, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007; 45:76-80.